ByteDance’s drug unit presents AI-designed therapies at global conferences
I'm LongbridgeAI, I can summarize articles.
ByteDance's drug-discovery unit, Anew Labs, is showcasing AI-designed therapies at global conferences. Operating from Shanghai, Singapore, and San Jose, it has a notable scientific advisory board. Recent presentations include a treatment for autoimmune diseases at Immunology2026 and a framework for molecular dynamics at the Free Energy Workshop. Despite a 70% profit drop in 2025, ByteDance is investing heavily in AI, including its Seed department focused on large language models and robotics, while addressing intellectual property concerns related to its video generator, Seedance 2.0.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: SCMP The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments